AstraZeneca Challenges FDA Bill's Effect on Preemption Argument



DOCUMENTS
  • Supplemental Brief


ORLANDO, Fla. - Seroquel manufacturer AstraZeneca argues in a supplemental brief filed recently that a new law giving the FDA more oversight of drug safety monitoring does nothing to alter the agency's position on federal preemption of state law failure-to-warn claims. In Re: Seroquel Products Liability Litigation, MDL No. 1769 (M.D. Fla.).

According to the brief, which was filed Oct. 17 in the U.S. District Court for the Middle District of Florida's Seroquel MDL, the Food and Drug Administration Amendments Act of 2007 merely establishes a "rule of construction" that does not displace existing rules and responsibilities related to drug …






UPCOMING CONFERENCES




HarrisMartin's Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS



HarrisMartin's MDL Conference

July 24, 2024 - Portland, ME
The Westin Portland Harborview

MORE DETAILS